New hope for rare cancer: drug combo shows promise in early trial
NCT ID NCT06232564
First seen Jan 26, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tests a new treatment for people with advanced high-grade neuroendocrine tumors, a rare and aggressive cancer. The treatment combines chemotherapy with an immunotherapy drug, followed by two maintenance drugs to keep the cancer under control. The goal is to see if this approach shrinks tumors and is safe for patients. The study involves 20 participants and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.